Kidney complications following COVID-19 vaccination; a review of the literature

Q3 Medicine Journal of Nephropharmacology Pub Date : 2021-08-30 DOI:10.34172/npj.2022.01
S. Hassanzadeh, A. Djamali, Leila Mostafavi, A. Pezeshgi
{"title":"Kidney complications following COVID-19 vaccination; a review of the literature","authors":"S. Hassanzadeh, A. Djamali, Leila Mostafavi, A. Pezeshgi","doi":"10.34172/npj.2022.01","DOIUrl":null,"url":null,"abstract":"\n Objective: To review the reported cases of kidney injury following vaccination for coronavirus disease 2019 (COVID-19) with a focus on renal pathology. Methods: We searched for case reports of kidney complications after COVID-19 vaccine in PubMed. Results: A total of 36 articles including 49 case reports were reported. These included minimal change disease (n=17), IgA nephropathy (IgAN) (n=15), IgA nephritis/vasculitis (n=5), ANCA glomerulonephritis/vasculitis (n=5), anti-glomerular basement membrane (GBM) nephritis (n=2), and 1 case of each granulomatous vasculitis, acute tubulointerstitial nephritis, scleroderma renal crisis, IgG4-related disease nephritis, and primary membranous nephropathy (MN). Conclusion: We give an overview of the reported cases of post-COVID-19 renal complications. Further investigations of the underlying pathogenesis of post-COVID-19 vaccination renal adverse events are required, as prompt workup, diagnosis, and treatment of patients with renal complications may lead to complete remission, prevent kidney failure, and long-term complications such as end-stage renal disease (ESRD). However, these complications are overall extremely rare and the benefit of vaccination outweighs the potential risks.","PeriodicalId":16388,"journal":{"name":"Journal of Nephropharmacology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nephropharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34172/npj.2022.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 4

Abstract

Objective: To review the reported cases of kidney injury following vaccination for coronavirus disease 2019 (COVID-19) with a focus on renal pathology. Methods: We searched for case reports of kidney complications after COVID-19 vaccine in PubMed. Results: A total of 36 articles including 49 case reports were reported. These included minimal change disease (n=17), IgA nephropathy (IgAN) (n=15), IgA nephritis/vasculitis (n=5), ANCA glomerulonephritis/vasculitis (n=5), anti-glomerular basement membrane (GBM) nephritis (n=2), and 1 case of each granulomatous vasculitis, acute tubulointerstitial nephritis, scleroderma renal crisis, IgG4-related disease nephritis, and primary membranous nephropathy (MN). Conclusion: We give an overview of the reported cases of post-COVID-19 renal complications. Further investigations of the underlying pathogenesis of post-COVID-19 vaccination renal adverse events are required, as prompt workup, diagnosis, and treatment of patients with renal complications may lead to complete remission, prevent kidney failure, and long-term complications such as end-stage renal disease (ESRD). However, these complications are overall extremely rare and the benefit of vaccination outweighs the potential risks.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新冠肺炎疫苗接种后的肾脏并发症;文献综述
目的:回顾2019冠状病毒病(新冠肺炎)疫苗接种后肾损伤的报告病例,重点关注肾脏病理学。方法:在PubMed检索新冠肺炎疫苗接种后肾脏并发症的病例报告。结果:共报道36篇文章,包括49例病例报告。其中包括微小变化性疾病(n=17)、IgA肾病(IgAN)(n=15)、IgA肾炎/血管炎(n=5)、ANCA肾小球肾炎/血管炎症(n=五)、抗肾小球基底膜(GBM)肾炎(n=2),每种肉芽肿性血管炎、急性肾小管间质性肾炎、硬皮病肾危象、IgG4相关疾病肾炎和原发性膜性肾病(MN)各1例。结论:我们概述了COVID-19后肾脏并发症的报告病例。需要对COVID-19疫苗接种后肾脏不良事件的潜在发病机制进行进一步研究,因为对肾脏并发症患者的及时检查、诊断和治疗可能会导致完全缓解,预防肾衰竭和长期并发症,如终末期肾病(ESRD)。然而,这些并发症总体上极为罕见,接种疫苗的益处大于潜在风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Nephropharmacology
Journal of Nephropharmacology Medicine-Pharmacology (medical)
CiteScore
1.70
自引率
0.00%
发文量
18
审稿时长
4 weeks
期刊最新文献
Evaluation of the effect of montelukast drug in improving the clinical condition of patients with COVID-19 in referral hospitals in Isfahan; a randomized clinical trial Renal insufficiency in breast cancer patients; a review study The Mayo Clinic consensus report on membranous nephropathy; a promising step toward better treating the disease Emerging cancer in individuals with cardiovascular disease: Exploring the intersection of reverse cardio-oncology and nephropharmacology Oncocardiology: close collaboration between oncologists, cardiologists, and nephrologists
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1